Clinical Trial Update: A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Isatuximab (Sarclisa) (isatuximab)
• Venetoclax (Venclyxto) (venetoclax)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Status: RECRUITING